Search company, investor...
Kymab company logo


Founded Year



Acquired | Acquired

Total Raised




About Kymab

Kymab is a clinical-stage biopharmaceutical company developing a deep pipeline of human antibody-based therapies in a broad range of indications. Its platforms generate a vast repertoire of fully-human, species cross-reactive and affinity-matured antibodies against challenging targets.On January 11th, 2021, Kymab was acquired by Sanofi at a valuation between $1100M and $1450M.

Headquarters Location

The Bennet Building (B930) Babraham Research Campus

Cambridge, England, CB22 3AT,

United Kingdom

+44 (0)1223 833301

Missing: Kymab's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kymab's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kymab

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kymab is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kymab Patents

Kymab has filed 1 patent.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Experimental cancer drugs



Latest Kymab News

Safety data show Adbry well tolerated in treatment of moderate to severe atopic dermatitis

Nov 8, 2022

Disclosures: Simpson reports having financial relationships with Advances in Cosmetic Medical Derm Hawaii LLC, AbbVie, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Boehringer Ingelheim USA, Inc., Boston Consulting Group, Bristol Myers Squibb – BMS, Castle Biosciences, Collective Acumen, LLC (CA), CorEvitas, Dermavant, Dermira, Eli Lilly, Evelo Biosciences, Evidera, Excerpta Medica, FIDE, Forte Bio RX, Galderma, Gesellschaft Z, GlaxoSmithKline, Incyte, Janssen, Johnson & Johnson, Kymab, Kyowa Kirin, LEO Pharma, Medscape LLC, Merck, Maui Derm, MLG Operating, MJH holding, National Jewish Health, Pfizer, Physicians World LLC, PRImE, Regeneron, Revolutionizing Atopic Dermatitis Inc, Roivant, Sanofi-Genzyme, Target RWE, Trevi therapeutics, Valeant, Vindico Medical Education and WebMD. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study. Adbry (tralokinumab, LEO Pharma) is the only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine, one of the drivers of atopic dermatitis . The results of pooled safety data for tralokinumab showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis. “We know that moderate to severe atopic dermatitis is not a 16-week disease. It’s often a 16-year or a lifetime disease, so we need data to make us comfortable with chronic treatment,” Eric L. Simpson, MD, MCR, Frances J. Storrs Medical Dermatology Professor and director of the OHSU Dermatology Clinical Research Center School of Medicine at Oregon Health & Science University, told Healio. “We’ve found that, with tralokinumab, the blockade of IL-13 cytokine is an extremely safe option for long term therapy for moderate to severe atopic dermatitis.” Eric Simpson Published in the British Journal of Dermatology, the analysis pooled data from five randomized, double-blind, placebo-controlled trials — three pivotal phase 3 trials, a phase 2 trial and a phase 2b trial. In total, the studies randomly assigned 2,285 patients to tralokinumab (n = 1,605) or placebo (n = 680). During the 16-week initial treatment period, the frequencies of any adverse events were 65.7% for tralokinumab and 67.2% for placebo. Serious adverse events were reported in 2.1% of the tralokinumab groups and 2.8% of the placebo groups. The most common adverse events reported more frequently with tralokinumab compared with placebo included viral upper respiratory tract infection (15.7% vs. 12.2%), upper respiratory tract infection (5.6% vs. 4.8%), conjunctivitis (5.4% vs. 1.9%) and injection-site reaction (3.5% vs. 0.3%). Those treated with tralokinumab vs. placebo saw lower rates of skin infections requiring systemic treatment (2.6% vs. 5.5%), eczema herpeticum (0.3% vs. 1.5%), opportunistic infections (3.4% vs. 4.9%) and serious infections (0.4% vs 1.1%). Tralokinumab outperformed placebo in safety over time with no significant changes in adverse events. “The adverse event rate in the long term is lower than the short term. And so, your rates of adverse events do not increase over time. In fact, they reduce significantly,” Simpson said. “You could make the claim that Adbry is a safer drug with more prolonged treatment.” Read more about

Kymab Frequently Asked Questions (FAQ)

  • When was Kymab founded?

    Kymab was founded in 2010.

  • Where is Kymab's headquarters?

    Kymab's headquarters is located at The Bennet Building (B930), Cambridge.

  • What is Kymab's latest funding round?

    Kymab's latest funding round is Acquired.

  • How much did Kymab raise?

    Kymab raised a total of $209M.

  • Who are the investors of Kymab?

    Investors of Kymab include Sanofi, LifeArc, Bill & Melinda Gates Foundation, Wellcome Trust, Woodford Investment Management and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.